Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
about
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsRegulation of translocator protein 18 kDa (TSPO) expression in health and disease statesExpression of PTRF in PC-3 Cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways.Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cellsReduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway.Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferationPost-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivorsIntegrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma.Statins and breast cancer stage and mortality in the Women's Health Initiative.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems.HMG-CoA reductase inhibitor lovastatin causes reversible cytoskeleton perturbation by RhoA signalling suppression in peritoneal cell line Met5A.Rho GTPases as therapeutic targets in cancer (Review).Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.
P2860
Q21093314-4FB2F664-1C03-4BC4-A5F5-0D4B36DD0F1AQ24631648-B8334005-FF25-41CC-A229-4B20BDD66E21Q34059317-0D4E2077-01BE-4A90-8AF5-C50EC46ABB8FQ34164712-6C18381E-2249-4BAC-A400-E710411D72B1Q34174418-6DA6BC7D-6CFD-41E9-826A-816D502A0A48Q35287780-8C1DC15C-3DB2-4361-A377-3A9870090BB3Q35550354-61BD4285-26B6-48C9-8FEF-E79CC3BE1FDFQ36426544-9B31AF60-20BF-4B4B-B265-7FA4E977FA39Q36729421-A42BBD71-B317-428C-BA11-D7E6E80F425AQ37324459-7F271C0D-78FE-4E0A-BB9A-BDCC346058F8Q37734257-F9568E87-923E-4571-8F9B-B167C08DDD2BQ38572098-7B995E70-2736-48C8-B85A-91BF0DE1CD31Q39705806-6D1352D2-D018-438D-B9B1-D9E9D0DA80E1Q41387997-C4E786BB-FB2F-4838-9FFE-183F4A87C9E4Q50198264-2A99677B-2EF8-4E81-8B48-FD88838779E6Q53788180-06925B02-CFDB-4985-8B90-5D571F6771DF
P2860
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@en
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@nl
type
label
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@en
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@nl
prefLabel
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@en
Lovastatin alters cytoskeleton ...... is of mammary carcinoma cells.
@nl
P356
P1476
Lovastatin alters cytoskeleton ...... sis of mammary carcinoma cells
@en
P2093
Débora R Bublik
Hernán G Farina
P2888
P304
P356
10.1023/A:1020355621043
P577
2002-01-01T00:00:00Z
P6179
1034437624